Market Segmentation:
- By Service Type
- Biorepository Services
- Archiving Solutions
- Sample Management
- Data Management
- Consulting Services
- Others (e.g., Logistics, Quality Control)
- By Sample Type
- Blood Products
- Human Tissues
- Nucleic Acids
- Cell Lines
- Biological Fluids
- Others (e.g., Microorganisms, Plant Tissues)
- By Application
- Drug Discovery & Development
- Diagnostics
- Personalized Medicine
- Population Health Studies
- Regenerative Medicine
- Others (e.g., Toxicology Studies, Biomarker Validation)
- By Storage Type
- Manual Storage Systems
- Automated Storage Systems
- Cryogenic Storage Systems
- Refrigerated Storage Systems
- Ambient Temperature Storage
- Others (e.g., Controlled Room Temperature)
- By End User
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic & Research Institutions
- Hospitals & Diagnostic Centers
- Others (e.g., Biobanks, Government Organizations)
- By Specimen Scale
- Small-scale Biorepositories
- Medium-scale Biorepositories
- Large-scale Biorepositories
- By Ownership Model
- Commercial Biorepositories
- Academic/Institutional Biorepositories
- Public/Government Biorepositories
- Collaborative/Networked Biorepositories
- Others (e.g., Non-profit, Disease-specific)
- By Regions
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The current market size is US$ 2.8 Bn as of 2024.
Increasing clinical trials, demand for personalized medicine, biobanking advancements, focus on biomarker discovery, and growing biopharma R&D investments.
Stringent regulations, high costs, ethical concerns, data management challenges, sample quality issues, limited standardization, and skilled workforce shortages.
The leading component segment is Storage Services, crucial for maintaining sample integrity throughout clinical trials.
Brooks Life Sciences, Thermo Fisher Scientific, BioStorage Technologies (LabCorp), Precision for Medicine, Q2 Solutions, IQVIA, and Charles River Laboratories.
The market is projected to grow at a CAGR of 9.12% from 2024 to 2031, reaching US$ 5.3Bn by 2031.
Increasing clinical trials, personalized medicine demand, biobanking advancements, biomarker discovery focus, and growing biopharma R&D investments.